SAGE Therapeutics (SAGE) Tops Q1 EPS by 70c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Sage Therapeutics Announces First Quarter 2020 Financial Results and Highlights Pipeline and Business Progress
May 7, 2020 4:01 PM EDTExpected initiation of three new short-term zuranolone clinical studies in 2020, with the potential for three distinct indications
April restructuring to advance corporate strategy and pipeline expected to result in approximate annualized cost savings of $170M, with significant portion related to ZULRESSO commercial and G&A support
Progress continues in neurology and neuropsychiatry franchises with planned initiation of Phase 2 clinical trials of SAGE-324 in 1H and SAGE-718 in 2H, 2020
Mike Cloonan elevated to chief operating officer
Conference call today at 4:30... More
